Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026195 · ClinicalTrials.gov registry record · Phase 1
Irinotecan in Treating Aging Patients With Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT00026195 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 140 participants, below the 499-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00026195, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Aging may affect the way these drugs work. PURPOSE: Phase I trial to determine the relationship between aging and the effectiveness of irinotecan in treating patients who have solid tumors.
Conditions Studied
Interventions
- DRUG irinotecan hydrochloride
Study Locations (20)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- Veterans Affairs Medical Center - San Francisco - San Francisco
- UCSF Comprehensive Cancer Center - San Francisco
Illinois
- MBCCOP - University of Illinois at Chicago - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
District of Columbia
- Lombardi Cancer Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts Memorial Medical Center - University Campus - Worcester
Minnesota
- Veterans Affairs Medical Center - Minneapolis - Minneapolis
- University of Minnesota Cancer Center - Minneapolis
Missouri
- Veterans Affairs Medical Center - Columbia (Truman Memorial) - Columbia
- Ellis Fischel Cancer Center - Columbia - Columbia
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Florida
- CCOP - Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2001-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026195
The ClinicalTrials.gov registry entry for NCT00026195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (72% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which irinotecan hydrochloride is the first listed.
NCT00026195 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00026195 about?
NCT00026195 is a clinical study titled "Irinotecan in Treating Aging Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Aging may affect the way these drugs work. PURPOSE: Phase I trial to determine the relationship between aging and the effectiveness of irinotecan in treating patients who have sol...
What is the current status of trial NCT00026195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2001-09. Estimated completion is 2006-06.
What conditions does trial NCT00026195 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00026195?
The interventions under investigation include: irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00026195?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026195 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.